TRDA NASDAQ
Entrada Therapeutics, Inc.
1W: -7.6%
1M: -51.6%
3M: -44.1%
YTD: -37.2%
1Y: -23.4%
3Y: -51.8%
$6.56
+0.25 (+3.96%)
Weekly Expected Move ±30.2%
$3
$4
$6
$8
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (28)
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Dow Dips 350 Points; US Foods Posts Downbeat Earnings
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why
12 Health Care Stocks Moving In Thursday's Intraday Session
Entrada plunges after early-stage trial data for Duchenne therapy
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Entrada Therapeutics GAAP EPS of -$0.95, revenue of $0.9M
Entrada Therapeutics Reports First Quarter 2026 Financial Results
Entrada Therapeutics Reports First Quarter 2026 Financial Results
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Cantor Fitzgerald L. P. Makes New Investment in Entrada Therapeutics, Inc. $TRDA
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of “Moderate Buy” from Analysts
HC Wainwright Has Optimistic Outlook of TRDA Q1 Earnings
Entrada Therapeutics GAAP EPS of -$0.94 beats by $0.30, revenue of $1.3M misses by $6.11M
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit
Entrada Therapeutics to Present at Upcoming Investor Conferences
Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)